Panelists discuss how addressing current knowledge gaps and improving real-world integration of emerging therapies will advance care for patients with EGFR-mutant non–small cell lung cancer (NSCLC).
Videos
Join the 43rd Annual Chemotherapy Foundation Symposium in New York City for cutting-edge cancer care education and networking opportunities.
Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues and achalasia in patients.
Dr. Michael Soulen discusses safety concerns and adverse events in neuroendocrine tumor treatments, highlighting cytopenia and radiation risks while ensuring patient safety.
A panelist discusses how novel bispecifics and ADCs signal a more hopeful future for ES-SCLC management.
Panelists discuss long-term efficacy and safety outcomes from pivotal studies evaluating dual immune checkpoint inhibition in advanced melanoma.
A panelist discusses how lurbinectedin and tarlatamab both remain essential options within evolving treatment strategies.
Chandler H. Park, MD, discusses real-world data for maintenance avelumab in bladder cancer and factors that sway his treatment selection.
Jason S. Starr, DO, discusses the significance of the extrapancreatic neuroendocrine tumor cohort of the phase 3 CABINET trial of cabozantinib.
A novel treatment combining chemotherapy and PRRT shows promising safety and efficacy for neuroendocrine tumors, with high response rates and ongoing trials.
Panelists discuss how dose optimization and personalized adjustment strategies sustain efficacy and enhance long-term outcomes in EGFR-mutant NSCLC.
Panelists discuss how proactive adverse event prevention and patient support improve tolerability and continuity of targeted treatment in EGFR-mutant non–small cell lung cancer (NSCLC).
Experts explore a novel combined therapy for liver-dominant neuroendocrine tumors, enhancing treatment durability with chemotherapy and PRRT.
Dr. Jonathan Strosberg discusses the promising results of the ALPHAMEDIX-02 trial, evaluating a new therapy for advanced neuroendocrine tumors.
Vivek Subbiah emphasizes tumor-agnostic therapies' potential to revolutionize cancer treatment by targeting genetic biomarkers, ensuring equitable access to precision medicine.
Experts discuss the importance of collaboration in improving surgical standards and treatment outcomes for neuroendocrine tumors through the CUTNETs initiative.
Healthcare professionals adjust octreotide and lanreotide doses for effective symptom control in patients with carcinoid syndrome, following NCCN guidelines.
Mary Maluccio, MD, MPH, FACS, discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 trial and ongoing patient follow-up.
Dr Mary Maluccio discusses promising results and safety concerns from the ALPHAMEDIX-02 trial on innovative therapy for GEP-NETs.
A panelist discusses how proactive management of CRS and ICANS supports safe community use of DLL3-targeted therapy.
A panelist discusses how tarlatamab’s strong efficacy data suggest a practice-changing advance for relapsed ES-SCLC.
Panelists discuss current frontline therapeutic strategies for advanced melanoma, highlighting the rationale and evolution of combination immunotherapy approaches.
New trial results reveal ITM-11 significantly improves survival rates in GEP-NET patients, outperforming everolimus with better efficacy and safety profiles.
A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell carcinoma, despite higher toxicity risks.
A new study reveals that combining TAR-200 with cetrelimab significantly improves treatment outcomes for muscle-invasive bladder cancer patients.
Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns and the need for further research.
Explore the latest insights on somatostatin analogs, dose adjustments, and emerging treatments for managing carcinoid syndrome symptoms effectively.
Panelists discuss how molecular testing and biomarker profiling guide individualized first-line treatment planning for EGFR-mutant non–small cell lung cancer (NSCLC) with central nervous system (CNS) involvement.
AI transforms healthcare by personalizing treatment plans and enhancing patient-provider communication, revolutionizing how we approach medical care.
Pierre Gholam, MD, associate professor of medicine at Case Western Reserve University School of Medicine, discusses his approach to recognizing and managing adverse events in patients receiving tyrosine kinase inhibitors for hepatocellular carcinoma.